Upneeq is an ophthalmic solution owned by Rvl Pharms, first authorized for market use on 08 July, 2020. It contains the active ingredient oxymetazoline hydrochloride and is primarily used for the non-surgical treatment of blepharoptosis. Upneeq holds a total of 12 patents, none of which have expired.
The generic version of Upneeq is expected to be available after 16 December, 2039. This is due to the expiration of its patent titled 'Oxymetazoline compositions', which holds the latest expiry date among all the enlisted patents.
Upneeq is utilized in the medical field as a method of treating blepharoptosis, a condition involving the drooping or falling of the upper eyelid. The active ingredient, oxymetazoline hydrochloride, contributes to the drug's effectiveness by stimulating the muscles that can lift the eyelid.
The last patent of Upneeq, titled 'Oxymetazoline compositions', is set to expire on 16 December, 2039. This will likely pave the way for the release of Upneeq generic versions. Below is the detail of the patent: